Sareum (LON:SAR) Issues Quarterly Earnings Results

Sareum (LON:SAR) announced its earnings results on Tuesday. The company reported GBX (0.90) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Sareum Trading Up 4.3 %

LON SAR opened at GBX 12.52 ($0.16) on Thursday. Sareum has a 1 year low of GBX 10 ($0.13) and a 1 year high of GBX 52.50 ($0.68). The company has a fifty day simple moving average of GBX 17.82 and a 200 day simple moving average of GBX 23.19. The company has a market cap of £15.64 million, a P/E ratio of -2.96 and a beta of -1.08.

Insider Buying and Selling

In other Sareum news, insider Stephen Parker bought 84,033 shares of the stock in a transaction on Wednesday, March 26th. The shares were purchased at an average price of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). Insiders own 5.02% of the company’s stock.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.